Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<p>A novel mutation panel for predicting etoposide resistance in small-cell lung cancer</p>

1 Jun 2019

Abstract excerpt

Purpose: Platinum-based chemotherapy, consisting of etoposide and cisplatin (EP), has been the cornerstone of therapy for extensive-stage small-cell lung cancer (ES-SCLC) for decades. Despite the marked initial sensitivity of SCLC to chemotherapy, EP regimens cannot avoid the emergence of drug resistance in clinical practice. With the rise of new chemotherapy regimens in recent years and the primary resistance or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31417239
DOI: 10.2147/dddt.s205633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<p>A novel mutation panel for predicting etoposide resistance in small-cell lung cancer</p>PMID 31417239Read ↗

Applications of Machine Learning to Predict Cisplatin Resistance in Lung CancerSemantic proximity Read ↗

Applications of Machine Learning to Predict Cisplatin Resistance in Lung CancerSemantic proximity Read ↗

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.Semantic proximity Read ↗

Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.Semantic proximity Read ↗

Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung CancerSemantic proximity Read ↗

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.Semantic proximity Read ↗

[Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].Semantic proximity Read ↗

eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer.Semantic proximity Read ↗

Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung CancerSemantic proximity Read ↗

Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting <i>ATG4A</i>Semantic proximity Read ↗

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.Semantic proximity Read ↗

Mitochondrial dysfunction rather than mtDNA sequence mutation is responsible for the multi-drug resistance of small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.